aMMP-8 Oral Fluid PoC Test in Relation to Oral and Systemic Diseases

Timo Sorsa; Solomon Olusegun Nwhator; Dimitra Sakellari; Andreas Grigoriadis; Kehinde Adesola Umeizudike; Ella Brandt; Mutlu Keskin; Taina Tervahartiala; Pirjo Pärnänen; Shipra Gupta; Ritin Mohindra; Nagihan Bostanci; Nurcan Buduneli; Ismo Tapani Räisänen

doi:10.3389/froh.2022.897115

aMMP-8 Oral Fluid PoC Test in Relation to Oral and Systemic Diseases

Front Oral Health. 2022 Jun 10:3:897115. doi: 10.3389/froh.2022.897115. eCollection 2022.

Authors

Timo Sorsa^{1

2}, Solomon Olusegun Nwhator³, Dimitra Sakellari⁴, Andreas Grigoriadis^{4

5}, Kehinde Adesola Umeizudike⁶, Ella Brandt¹, Mutlu Keskin⁷, Taina Tervahartiala¹, Pirjo Pärnänen¹, Shipra Gupta⁸, Ritin Mohindra⁹, Nagihan Bostanci², Nurcan Buduneli¹⁰, Ismo Tapani Räisänen¹

Affiliations

¹ Department of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
² Section of Oral Health and Periodontology, Division of Oral Diseases, Department of Dental Medicine, Karolinska Institutet, Solna, Sweden.
³ Department of Preventive and Community Dentistry, Obafemi Awolowo University, Ile-Ife, Nigeria.
⁴ Department of Preventive Dentistry, Periodontology and Implant Biology, Dental School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ 424 General Army Hospital, Thessaloniki, Greece.
⁶ Department of Preventive Dentistry, Faculty of Dental Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.
⁷ Oral and Dental Health Department, Altinbaş University, Istanbul, Turkey.
⁸ Oral Health Sciences Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
⁹ Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
¹⁰ Department of Periodontology, Faculty of Dentistry, Ege University, Izmir, Turkey.

Abstract

The manuscript uses the previously published literature and highlights the benefits of active-matrix metalloproteinase (aMMP)-8 chairside/point-of-care (PoC) diagnostic tools as adjunctive measures in oral and systemic diseases. Previous studies suggest that as a biomarker, aMMP-8 is more precise than total MMP-8, MMP-9, MMP-2, MMP-3, MMP-13, MMP-7, MMP-1, calprotectin, myeloperoxidase (MPO), human neutrophil elastase (HNE), tissue inhibitor of matrix metalloproteinase (TIMP)-1, and bleeding of probing (BOP). Therefore, aMMP-8 could be implemented as the needed key biomarker for the new disease classification for both periodontitis and peri-implantitis. With a sensitivity to the tune of 75-85% and specificity in the range of 80-90%, lateral flow aMMP-8 PoC testing is comparable to catalytic protease activity assays for aMMP-8. The test can be further applied to estimate the glycemic status of an individual, to ascertain whether a person is at risk for COVID-19, in managing the oral side effects of radiotherapy carried in head and neck cancers, and in selected cases pertaining to reproductive health. In the future, aMMP-8 could find application as a potential systemic biomarker in diseases affecting the cardiovascular system, cancers, bacteremia, sepsis, diabetes, obesity, meningitis, as well as pancreatitis. The aMMP-8 PoCT is the first practical test in the emerging new dental clinical field, that is, oral clinical chemistry representing oral medicine, clinical chemistry, peri-implantology, and periodontology.

Keywords: aMMP-8; biomarker; peri-implantitis; periodontitis; point-of-care (PoC); systemic diseases.

Publication types

Review